Anti-integrin Therapy
Anti-integrin Therapy - Related Videos
01:10
Integrins
0 Views •
2023
Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM. Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
01:15
Activation of Integrins
0 Views •
2023
Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling." In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
09:14
Static Adhesion Assay for the Study of Integrin Activation in T Lymphocytes
0 Views •
Cited by 21 •
2014
Static adhesion assay is a powerful tool that can be used to model the interactions between T lymphocytes and other cell types. Interactions are generated by injecting labeled T cells into wells coated with adhesion molecules, while a plate reader is used to quantify the number of adherent cells following serial washes.
13:21
Antibody Generation: Producing Monoclonal Antibodies Using Hybridomas
0 Views •
2023
Source: Frances V. Sjaastad1,2, Whitney Swanson2,3, and Thomas S. Griffith1,2,3,4 1 Microbiology, Immunology, and Cancer Biology Graduate Program, University of Minnesota, Minneapolis, MN 55455 2 Center for Immunology, University of Minnesota, Minneapolis, MN 55455 3 Department of Urology, University of Minnesota, Minneapolis, MN 55455 4 Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455 Polyclonal antibodies are defined as a collection of antibodies directed against...
01:10
Antibody Structure
0 Views •
2019
Overview Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding. The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains Antibodies consist of four polypeptide chains: two identical heavy...
FAQs
Selectivity determines which integrin subunit or extracellular ligand an agent blocks, thereby narrowing the affected cell interactions. A target associated with leukocyte trafficking may reduce immune-cell entry into inflamed tissue, whereas interference with platelet-related integrin function may influence aggregation. This distinction helps pharmacologists connect a drug’s molecular target with its intended therapeutic effect and potential risks.
Leukocyte trafficking controls movement of immune cells into tissues. When an anti-integrin agent interferes with the relevant adhesion and migration interactions, fewer leukocytes may enter an inflamed organ, which can alter the local immune response. This mechanism is particularly relevant to pharmacological approaches for inflammatory bowel disease and multiple sclerosis, where tissue-specific inflammation contributes to disease activity.
The principal difference is the biological interaction being disrupted. Some agents are directed toward integrin pathways that support leukocyte adhesion and migration, changing immune-cell access to inflamed organs. Other integrin targets participate in platelet aggregation, so their inhibition addresses a vascular process instead. Target choice therefore links the same receptor family to distinct therapeutic goals and safety considerations.
Integrins contribute to normal cell adhesion, migration, and signaling as well as disease-associated inflammation. Blocking selected pathways can therefore reduce harmful immune-cell trafficking while also altering protective immune responses. Pharmacologists must weigh the benefit of limiting inflammation against the possibility that impaired immune-cell interactions could weaken host defense, making target specificity central to risk assessment.
Their application depends on the integrin pathway connected to the disease process. In inflammatory bowel disease and multiple sclerosis, the relevant therapeutic aim is to alter immune-cell trafficking or immune responses. In vascular disorders, investigators may focus on integrin functions involved in platelet aggregation. These uses illustrate how pharmacological target selection adapts one receptor family to different clinical problems.
Evaluation can focus on whether the agent changes the intended cell interaction and produces the expected biological consequence. For immune-oriented targets, relevant outcomes include reduced leukocyte entry into inflamed organs or altered immune responses. For platelet-associated targets, investigators may examine effects on aggregation. They also assess whether pathway inhibition creates unwanted consequences, including impaired host defense.